OBJECTIVES: Arthritis is one of the most common chronic diseases among elderly. Approximately 50% of all elderly in the United States suffer from the disease. Drug therapy plays an important role in decreasing morbidity and mortality associated with the disease. The objectives of this study are to evaluate the effect of prescription drug insurance coverage on prescription drug use, and health among the elderly patients with arthritis. METHODS: Estimates are obtained using multivariate regression, and a fi xed-effect (within person) research design that controls for the unmeasured personspecifi c effects. Analyses were based on the Medicare Current Benefi ciary Survey for years [1992][1993][1994][1995][1996][1997][1998][1999][2000][2001][2002][2003][2004]. RESULTS: Estimates show that prescription drug coverage is associated with a 2%-15% increase in utilization of prescription drugs depending on the type and generosity of the coverage. In addition, the effect of drug coverage on drug use differed depending on the type of drugs, and other co-morbid conditions. For example, among arthritic patients, drug coverage increased use of diabetic drugs by 20%, whereas it had relatively low impact on use of cold medications (2%). We found no evidence that drug coverage improved hospitalization and general health status. CONCLUSIONS: Drug coverage plays a crucial role on the use of essential medications among elderly patients with arthritis. The results of the analysis also suggest the importance of controlling for selection bias. Our estimates on drug coverage were reduced markedly when we accounted for selection into plans.
PMS51 RETROSPECTIVE ANALYSIS OF INFLIXIMAB DOSING AND INFUSION PATTERNS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A COMMERCIALLY-INSURED POPULATION
Carter C 1 , Tang B g 1 , Changolkar A 2 , McKenzie RS 1 , Piech CT 1 1 Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2 SOAL PharmaTech Solutions, LLC, Philadelphia, PA, USA OBJECTIVES: To determine the mean induction and maintenance infl iximab (IFX) dose per infusion and infusion patterns in patients with rheumatoid arthritis (RA) enrolled in commercial health plans. METHODS: Medical/pharmacy claims (January 1, 2000 and December 31,2006) were obtained from a national commercial benchmark database. Inclusion criteria were patient age 18, 2 RA diagnosis codes, no medical/pharmacy claims of biologic use during 6 months prior to IFX index date (which occurred on or after fi rst RA diagnosis date) and 365 days of IFX persistence. Patients were excluded if they had a diagnosis of ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, or ulcerative colitis. Infused doses were calculated by dividing the plan's allowed amount per IFX claim (HCPCS code J1745) by the acquisition cost for a 100 mg vial during the year of payment. Results were reported for induction (weeks 0-8), maintenance (weeks 9-52), and one-year time periods (weeks 0-52). Infusion patterns included the mean days between each infusion during the fi rst year of treatment. RESULTS: A total of 457 RA patients were identifi ed (mean age 53 years; 74% female). A total of 425 evaluable patients with no missing infusion data were included in the dosing analysis. The mean IFX dose per infusion was 397, 455, and 437 mg for induction, maintenance, and one-year periods, respectively. A total of 98.5% of IFX-treated patients received 8 infusions during fi rst year. Mean time between IFX infusions were as follows: 1st and 2nd 19 days; 2nd and 3rd 29 days; 3rd and 4th 56 days; 4th and 5th 57 days; 5th and 6th 55 days; 6th and 7th 52 days; 7th and 8th 53 days. CONCLUSIONS: This observational study reported IFX infusion patterns consistent with prescribing information which is useful for stakeholders' understanding of real world IFX utilization. 
PMS52 NSAIDS CONSUMPTION IN CROATIA: THE EFFECTS OF PRICING POLICY CHANGES

PMS53 DISPARITIES IN MAJOR JOINT REPLACEMENT SURGERY AMONG ENROLLEES WITH AARP MEDICARE SUPPLEMENT INSURANCE
Hawkins K 1 , Escoto KH 2 , Ozminkowski RJ 3 , Bhattarai GR 4 , Migliori RM 5 1 Ingenix, Brooklyn, MI, USA, 2 Ingenix, Eden Prairie, MN, USA, 3 UnitedHealth Group Alliances, Ann Arbor, MI, USA, 4 Ingenix, Rocky Hill, CT, USA, 5 UnitedHealth Group Alliances, MINNETONKA, MN, USA OBJECTIVES: Determine if disparities in hip and knee replacement surgery exist among osteoarthritis patients with Medicare supplement plan coverage (i.e., Medigap). METHODS: Data were obtained from UnitedHealth Group's database of AARP Medicare Medigap insureds. Patients were selected into the study if they had one or more medical claims with a diagnosis of osteoarthritis from July 1, 2006 -June 30, 2007 . Logistic regression analyses tested for age-, gender-, race-, or income-related differences in the likelihood of receiving a hip or knee replacement surgery. The regression models controlled for socioeconomics, health status, type of supplement plan, and residential location. RESULTS: Of the 2.2 million Medigap insureds eligible for the study, 529,652 (24%) had osteoarthritis. Of these, 32,527 (6.1%) received a hip or knee replacement surgery. Males were 6% (p 0.001) more likely than females to have a replacement surgery. Patients residing in minority or lower-income neighborhoods were less likely to receive a hip or knee replacement surgery. The surgery rate decreased with age. Supplement plan type was not a strong predictor of the likelihood of hip or knee replacement. Disparities were much greater by comorbid condition and residential location. Obese patients were 1.79 (p 0.001) times as likely, whereas patients with COPD were only 0.69 times (p 0.001) as likely to have a hip or knee replacement. Patients in rural areas were 14% (p 0.001) less likely than those in urban areas and patients residing in South Dakota, Idaho, and Alaska were 3.24 (p 0.001), 2.58 (p 0.001), and 2.49 (p 0.001) more likely than those in New Jersey to have replacement surgery. CONCLUSIONS: Disparities in hip and knee replacement surgery existed by age, gender, race, and income levels. Larger disparities were found by residential location and comorbid condition. AARP and UnitedHealth Group are designing interventions to address these disparities; these interventions will begin in mid-2009.
